This study focuses on people who have undergone a kidney transplant, which is a surgical procedure where a healthy kidney from a donor is placed into a person whose own kidneys no longer work properly. The research aims to determine the effect of dapagliflozin compared to a placebo when added to standard medical care. A specific concern in this group is the development of post-transplant diabetes mellitus, a type of high blood sugar that can occur after receiving a new kidney. The study also looks at kidney allograft function, which refers to how well the transplanted kidney is working.

Participants will be assigned to receive either dapagliflozin or a placebo in the form of an oral tablet. Throughout the study, various health factors will be monitored, such as eGFR, which is a measure used to check how well the kidneys are filtering blood, and proteinuria, which is the presence of excess protein in the urine. Other areas of interest include monitoring creatinine levels, a waste product in the blood that indicates kidney health, and checking for cholesterol levels. The study will also track blood pressure, the force of blood against artery walls, and the occurrence of any urinary tract infection.

The research will continue for a set period to observe changes in health outcomes. This includes monitoring for kidney transplant rejection, where the body’s immune system attacks the new organ, and checking for end-stage renal disease, a condition where the kidneys can no longer support the body’s needs. Additionally, the study will track major adverse cardiac events, which are serious heart-related problems, and general safety through the reporting of adverse events. The participants will receive regular follow-ups to ensure all necessary measurements are taken over the course of the trial.